Pentostam

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2004
Highly Cited
2004
Arsenicals and antimonials are first line drugs for the treatment of trypanosomal and leishmanial diseases. To create the active… (More)
Is this relevant?
2001
2001
In both scid and BALB/c mouse-Leishmania donovani models, hexadecyphosphocholine (miltefosine) and AmBisome had similar levels of… (More)
  • figure 1
  • table 1
Is this relevant?
Highly Cited
2001
Highly Cited
2001
The standard treatment of human visceral leishmaniasis involves the use of pentavalent antimony (Sb(V)). Its mechanism of action… (More)
  • table I
  • figure 1
  • table II
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2000
Highly Cited
2000
A quantitative colorimetric assay using the oxidation-reduction indicator Alamar Blue was developed to measure cytotoxicity of… (More)
Is this relevant?
1997
1997
An axenic amastigote culture system was utilized to directly assess the stage-specific antileishmanial effects of antimony on… (More)
  • figure 1
  • figure 2
  • figure 4
  • figure 3
  • table 1
Is this relevant?
Highly Cited
1995
Highly Cited
1995
Successful treatment in allergic, autoimmune, and infectious diseases often requires altering the nature of a detrimental immune… (More)
  • figure 1
  • figure 3
Is this relevant?
Highly Cited
1992
Highly Cited
1992
To determine the relative efficacy and toxicity of stibogluconate and ketoconazole for the treatment of cutaneous leishmaniasis… (More)
Is this relevant?
1989
1989
Promastigotes of Leishmania mexicana amazonensis WR 669 clone 4 were made resistant to antimony in the form of Pentostam (sodium… (More)
Is this relevant?
1989
1989
Antimony unresponsiveness in mucocutaneous and visceral leishmaniasis is a serious clinical problem. Information on the… (More)
Is this relevant?
1988
1988
The chemical properties of the primary antileishmanial agent sodium stibogluconate (Pentostam), and the interaction of Pentostam… (More)
Is this relevant?